Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
PaxMedica Inc | PXMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.6883 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.372 - 29.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.6883 | USD |
PaxMedica Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.11M | 7.41M | - | 0 | -18.29M | -2.47 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
PaxMedica News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PXMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 1.11 | 1.189 | 0.55 | 0.8252892 | 9,319,723 | -0.4217 | -37.99% |
3 Months | 0.514 | 1.189 | 0.4011 | 0.7858256 | 2,887,551 | 0.1743 | 33.91% |
6 Months | 2.33 | 4.45 | 0.372 | 0.950274 | 1,984,271 | -1.64 | -70.46% |
1 Year | 25.50 | 29.75 | 0.372 | 3.67 | 1,854,818 | -24.81 | -97.30% |
3 Years | 110.50 | 178.16 | 0.372 | 26.57 | 1,841,265 | -109.81 | -99.38% |
5 Years | 110.50 | 178.16 | 0.372 | 26.57 | 1,841,265 | -109.81 | -99.38% |
PaxMedica Description
PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. |